TP53 and cancer: There is nevertheless a wide range of sensitivity to the Mdm2/p53 binding inhibitors among TP53 wild-type cancer cell lines, which vary widely for different inhibitors (which in turn clearly emphasizes differences of the particular molecular mechanisms of action of different Mdm2-p53 inhibitors) [3].